FDA Accepts Progression Endpoint For Gemzar Ovarian Cancer Indication
Executive Summary
FDA's approval of Lilly's Gemzar to treat ovarian cancer - contrary to the advice of its Oncologic Drugs Advisory Committee - demonstrates the agency's willingness to accept progression-free survival as a clinically meaningful endpoint
You may also be interested in...
ODAC Says Toxicity Trumps Meager PFS And TTP Benefit for Yondelis, Doxil
Changing endpoints midway through the clinical trials for the two Centocor/Ortho Biotech oncology drugs reviewed by FDA's Oncologic Drugs Advisory Committee July 15 did not help their regulatory prospects - but in the end it was the poor efficacy and unacceptable toxicity that doomed both Yondelis and Doxil
ODAC Says Toxicity Trumps Meager PFS And TTP Benefit for Yondelis, Doxil
Changing endpoints midway through the clinical trials for the two Centocor/Ortho Biotech oncology drugs reviewed by FDA's Oncologic Drugs Advisory Committee July 15 did not help their regulatory prospects - but in the end it was the poor efficacy and unacceptable toxicity that doomed both Yondelis and Doxil
FDA Advisory Panels Off To Slow Start In 2007 After Role Change In 2006
FDA is on pace to hold fewer advisory committee meetings in 2007 than in 2006